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Summary
Objectives: To evaluate the clinical outcome and predictive factors of recurrence among
patients with Kikuchi’s disease.
Methods: Between January 2001 and December 2006, all patients with Kikuchi’s disease were
included in the study. Data were collected on co-morbidities, clinical manifestations, and
ultrasound/laboratory findings, and the differences were compared between recurrent disease
and non-recurrent disease groups.
Results: The study included 102 patients with a mean age of 26.7 years. Among these patients,
three developed systemic lupus erythematosus during the follow-up period, while two cases were
later associated with tuberculosis. Eight patients (7.8%) experienced early relapse and 13 (12.7%)
showed late recurrence. Patients with recurrent episodes were more likely to have fever and
fatigue with extranodal involvement. Compared to the non-recurrent cases, recurrent cases
remained symptomatic for a rather longer duration. The positive rate of the fluorescence anti-
nuclear antibody (FANA) test was significantly higher in the recurrent disease group compared to
the non-recurrent disease group.
Conclusions: Kikuchi’s disease took a self-limiting clinical course in most cases, but the recur-
rence rate found in the present study was higher than that of previous reports. Kikuchi’s disease
might be a phenotype of diverse disease entities. The prognosis is different according to the
underlying cause. The FANA test would be useful in predicting recurrence.
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Kikuchi’s disease is a benign, self-limiting disorder, which
is characterized by painful regional lymphadenopathy,ational Society for Infectious Diseases.
Recurrent Kikuchi s disease 323predominantly in the cervical region, accompanied by fever
and night sweats. In addition to the lymphadenopathy, a
variable percentage of patients (30—50%) may have low
grade fever associated with upper respiratory symptoms.1
Extranodal involvement is uncommon, but skin rash, hepa-
titis, arthritis, oral ulcers, and eye involvement have been
reported.1,2 Although most affected patients recover with-
out serious complications, some of them suffer from recur-
rent episodes of Kikuchi’s disease. A relatively low
recurrence rate has been described in 3—7% of cases.3—5
Recurrent episodes sometimes cause confusion in clinicians,
leading to concerns about the possibility of underlying
malignant lymphoma or autoimmune disease; a certain fol-
low-up period is necessary, which is not clearly defined.
This studywas designed to evaluate the clinical course and
outcome of Kikuchi’s disease. In the case of recurrence, we
evaluated the predictive factors of recurrence, making sug-
gestions for the appropriate follow-up period after the initial
episode.
Methods
Study design
From 1 January 2001 through 31 December 2006, all patients
with pathologically confirmed Kikuchi’s disease who attended
the Korea University Medical Center were included in the
study. Any cases having a follow-up period of less than 12
months were excluded. We reviewed the medical records
retrospectively. Kikuchi’s disease was defined as any case with
regional or generalized lymphadenopathy that showed com-
patible findings (aggregates of histiocytes and lymphoid cells
with abundant karyorrhectic debris) on histology in the
absence of clinical and laboratory data suggesting active
tuberculosis, lymphoma, or connective tissue disease at initial
presentation. Apoptotic plasmacytoid mononuclear cells
should be positive for CD68 and myeloperoxidase on immuno-
histochemical stain. Histopathologic findings were classified
into three stages — proliferative, necrotizing, and xanthoma-
tous type — as previously described.6,7 The proliferative stage
consists of various histiocytes, plasmacytoid monocytes, and
lymphoid cells with karyorrhectic nuclear fragments, while
cellular aggregates with coagulative necrosis indicate the
necrotizing stage. Cases with predominant foamy histiocytes
are classified as xanthomatous stage regardless of the pre-
sence or absence of necrosis. We defined recurrence as rede-
veloped symptomatic cervical lymphadenitis after at least 1
week from complete clinical resolution, which was stratified
into early relapse (within 3 months from disease onset) and
late recurrence. As for late recurrence, only biopsy-proven
cases were included, while cases were regarded as early
relapse based on clinical assessment.
Data collection
We collected data on accompanying symptoms, physical
findings, co-morbidities, sonographic findings, laboratory
results, histological findings, and clinical course. Following
this, we compared the differences in demographic, radiolo-
gical, and laboratory data between the recurrent disease and
non-recurrent disease groups.Statistical analysis
Data were analyzed using SPSS 10.0. A p-value of <0.05 was
considered statistically significant. The Student’s t-test was
used to compare quantitative data, and the Chi-square test
was used to compare qualitative variables. Multivariate ana-
lysis was carried out using a stepwise logistic regression
model.
Results
Patient characteristics
The demographic, clinical, and laboratory data at the time of
initial diagnosis of Kikuchi’s disease are presented in Table 1.
Among 137 patients with Kikuchi’s disease, 35 patients were
excluded from the analysis (26 follow-up loss and nine
patients with short-term follow-up). The study included
102 patients (22 male and 80 female subjects) with a mean
age of 26.7 years, ranging from 4 to 49 years. The onset of
Kikuchi’s disease was acute in 60 cases, while 42 cases were
subacute (evolved over a period of >2 weeks before visiting
the clinic). Patients complained of fever (38.0 8C, 73.5%),
sore throat (14.7%), cough (11.8%), and fatigue (12.7%).
Other manifestations were rare (less than 10%). As for the
involved lymph nodes, more than two thirds of patients
presented with multiple painful cervical lymphadenopathies,
but only four patients showed generalized lymphadenopathy:
simultaneous involvement of cervical lymph nodes with axil-
lary (or inguinal) lymph nodes. Diameters of the largest
lymph nodes were in the range of 1 to 5.5 cm (mean
1.81 cm). Extranodal involvement was noted among nine
patients: skin rash (two cases), oral ulcer (two cases), hepa-
titis (three cases), arthritis (one case), and meningitis (one
case). Patients usually complained of symptoms for about 5—
6 weeks (mean 39.1  20.3 days); symptomatic duration was
defined as the total period with either systemic symptoms
(fever, night sweat, myalgia, arthralgia, etc.) or painful
lymphadenopathy. Some cases were related to other medical
diseases such as thyroiditis, tuberculosis, systemic lupus
erythematosus (SLE), rheumatoid arthritis, or Behcet’s dis-
ease (Table 1). Except for thyroiditis, these developed later,
after the events of Kikuchi’s disease, during the follow-up
period.
With regards to the laboratory data, most patients
showed mild leukopenia and an increased level of acute
phase reactants (Table 2). Marked leukopenia (leukocyte
count less than 4  109/l) was observed in 53.5% (53/99
patients). Liver function tests were within the normal range
in 97.0% (96/99 patients). As for the lymph node ultrasound,
more than 80% were homogeneously enhancing lesions,
while central hilar architecture of the lymph node had
disappeared (either heterogeneous or hypoechoic) in
12.7% of cases. On histopathologic analysis, necrotizing type
was predominant (89.2%).
Patients were treated with non-steroidal anti-inflamma-
tory drugs (NSAIDs) and prednisolone for symptom relief,
which were maintained for 3—4 weeks (mean 23.2  16.9
days). NSAIDs, acetaminophen, steroid, and steroid com-
bined with NSAIDs were administered to 68 patients, 18
patients, six patients, and seven patients, respectively. No
Table 1 Demographic and clinical data of Kikuchi’s disease: comparison of epidemiological and clinical features between recurrent
and non-recurrent Kikuchi’s disease
Enrolled cases Recurrent
cases (N = 21)
Non-recurrent
cases (N = 81)
p-Value Total N = 102 (%)
Age, mean 26.1  7.2 26.9  9.2 0.70 26.7  8.8
Sex (male:female) 5:16 17:64 0.77 22 (21.6):80 (78.4)
Clinical onseta <0.01
Acute (<2 weeks) 6 54 60 (58.8)
Subacute (2 weeks) 15 27 42 (41.2)
Clinical manifestation
Fever (38.0 8C) 19 56 0.05 75 (73.5)
Cough 6 6 0.02 12 (11.8)
Sore throat 3 12 0.95 15 (14.7)
Night sweating 3 6 0.39 9 (8.8)
Weight loss (3 kg) 2 4 0.60 6 (5.8)
Fatigue 6 7 0.03 13 (12.7)
Myalgia 3 4 0.15 7 (6.9)
Headache 3 5 0.36 8 (7.8)
Lymph nodes
Number (S/M)b 2/19 9/72 0.83 11 (10.8)/91 (89.2)
Size (cm) 1.90  0.98 1.78  0.99 0.96 1.81  0.99
Generalizedc 2 2 0.19 4 (3.9)
Tenderness 17 67 0.85 84 (82.4)
Extranodal involvement 6 3 <0.01 9 (8.8)
Comorbiditiesd 0.78
Thyroiditis 0 5 0.58 5 (4.9)
Tuberculosis 0 2 0.98 2 (2.0)
Systemic lupus erythematosus 3 0 0.01 3 (2.9)
Rheumatoid arthritis 1 0 0.21 1 (1.0)
Behcet’s disease 1 0 0.21 2 (2.0)
Recurrence 21 (20.6)
Early (<3 months) - - - 8 (7.8)
Late (3 months) - - - 13 (12.7)
Treatment duration (mean days) 34.7  23.3 20.1  13.3 <0.01 23.0  16.8
Symptomatic duration (mean days)e 54.6  23.7 35.3  17.5 <0.01 39.1  20.3
a Acute (<2 weeks of symptoms before visiting any clinics); subacute (2 weeks of symptoms before visiting any clinics).
b Single/multiple.
c Simultaneous involvement of cervical and axillary (or inguinal) lymph nodes.
d Except for thyroiditis, these developed later, after the events of Kikuchi’s disease, during follow-up periods.
e Total period with either systemic symptoms or painful lymphadenopathy.
324 J.Y. Song et al.medication was prescribed for three patients. There were no
significant differences between the recurrent and non-recur-
rent disease groups with regards to medical therapy.
Predictive values of recurrent Kikuchi’s disease
Twenty-one patients (20.6%) experienced recurrent epi-
sodes of Kikuchi’s diseasewith disease-free intervals ranging
from 14 to 1210 days, averaging nine months. Among these,
eight cases (7.8%) showed early relapse and 13 cases (12.7%)
were late recurrence (Table 1). There was no significant
difference in follow-up period between the recurrent and
non-recurrent disease groups (mean 25.2 months vs. 27.3
months).
We tried to identify the predictive factors of recurrence
among patients with Kikuchi’s disease. On univariate analy-sis, patients with recurrent episodes weremore likely to have
fever, cough, and fatigue with frequent extranodal involve-
ment at initial presentation. These cases took a subacute
clinical course and remained symptomatic for a rather longer
duration (mean 54.6  23.7 vs. 35.3  17.5 days). Labora-
tory, radiological, and histological findings were indistin-
guishable between recurrent and non-recurrent groups. On
multivariate analysis, the presence of fatigue, extranodal
involvement, and long symptomatic duration were statisti-
cally significant as predictive factors of recurrence (Table 3).
Rheumatologic disease (three cases of SLE, one case of
rheumatoid arthritis, and two cases of Behcet’s disease)
was only noted in the recurrent group, whereas thyroiditis
was only noted in the non-recurrent group.
When we stratified the recurrent disease group into early
relapse and late recurrence, there were no remarkable
Table 3 Multivariate analysis for the predictive factors of recurrence among patients with Kikuchi’s disease
Enrolled cases Recurrent
cases (N = 21)
Non-recurrent
cases (N = 81)
OR (95% CI)
Clinical onseta 2.94 (0.71—11.36)
Acute (<2 weeks) 6 54
Subacute (2 weeks) 15 27
Fever 19 56 2.99 (0.48—18.72)
Cough 6 6 2.12 (0.31—14.77)
Fatigue 6 7 6.43 (1.25—33.12)
Extranodal involvement 6 3 8.29 (1.15—60.06)
Symptomatic durationb 54.6  23.7 35.3  17.5 1.05 (1.02—1.09)
OR, odds ratio; CI, confidence interval.
a Acute (<2 weeks of symptoms before visiting any clinics); subacute (2 weeks of symptoms before visiting any clinics).
b Total period with either systemic symptoms or painful lymphadenopathy, which persists despite medical treatment.
Table 2 Laboratory and radiological data of Kikuchi’s disease: comparison of laboratory and radiological data between recurrent
and non-recurrent Kikuchi’s disease
Enrolled cases Recurrent cases
(N = 21)
Non-recurrent
cases (N = 81)
p-Value Total
(N = 102)
WBC count ( 109/l) 3.574  1.346 4.271  1.287 0.49 4.077  1.333
Hemoglobin (g/dl) 12.5  1.02 15.8  22.43 0.48 14.9  19.1
Platelet count ( 109/l) 202  39 215  69 0.42 212  63
ESR (mm/h) 38.6  23.4 29.4  19.6 0.09 32.1  21.0
CRP (mg/l) 14.4  20.9 10.2  15.6 0.47 11.7  17.6
AST (IU/l) 25.8  10.9 31.0  57.6 0.69 29.4  48.2
ALT (IU/l) 21.6  11.8 31.9  67.2 0.51 28.8  56.3
ALP (IU/l) 63.7  20.5 80.3  96.4 0.51 75.1  80.9
Neck sonography (97 cases) 0.46
Preserved echogenic hilum 17 72 89 (87.3)
Loss of echogenic hilum 4 9 13 (12.7)
Biopsy finding 0.55
Necrotizing type 20 71 91 (89.2)
Proliferative type 1 7 8 (7.9)
Xanthomatous type 0 3 3 (2.9)
WBC, white blood cells; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; ALP, alkaline phosphatase.
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between the two subgroups.
In terms of the fluorescence anti-nuclear antibody (FANA)
test, which was performed in 46 cases, positive rates were
53.8% (7/13 cases) in the recurrent disease group and 21.2%
(7/33 cases) in the non-recurrent disease group ( p < 0.01).
Discussion
Kikuchi’s disease has been reported worldwide, and it is one
of the most common causes of cervical lymphadenitis in
Korea.1,8 According to the report by Kucukardali et al., most
cases have been reported from East Asia and the Far East
(50%), Europe (27%), and America (7%).8 Although infectious
etiologies including the Epstein—Barr virus, human herpes
virus 6, parainfluenza virus, Toxoplasma gondii, and Yersinia
enterocolitica have been suspected, the etiology of Kikuchi’s
disease still remains unclear.6,9—11 Likewise, the prognosis of
Kikuchi’s disease has been poorly evaluated.Though previous studies have reported low recurrence
rates of Kikuchi’s disease in the range of 3% to 7%, we have
experienced many recurrent cases in more recent years.3—5
For this reason we planned to evaluate the recurrence rate
and predictive factors for recurrence in patients with histo-
logically confirmed Kikuchi’s disease. In comparison with
previous studies, the recurrence rate was remarkably higher
in the present study. There are some presumptive reasons.
First, the cervical lymphadenopathy clinic is well organized
at the Korea University Medical Center, which might have
enabled doctors to monitor recurrences more efficiently.
Second, there is a chance that the more severe cases were
includedwith pathological confirmation, while themild cases
were excluded due to follow-up loss, thereby overestimating
the recurrence rate. Finally, early relapse cases were
included, which were clinically diagnosed.
With the results of the present study, wewere able to find
some important predictive factors for recurrent Kikuchi’s
disease: fever, fatigue, extranodal involvement, and long
326 J.Y. Song et al.symptomatic duration. Previously, Mohanty et al. reported
relapses that occurred within a few weeks after the first
episode,while Smith et al. observed relapses that developed
over a period of 2 to 10 years after the initial presenta-
tion.2,12—14 Contrary to previous reports, recurrences
occurred with various disease-free intervals after the initial
episode of cervical lymphadenitis. Though therapeutic
guidelines are not established, we assumed that early
relapse (within 3 months) might have been due to insuffi-
cient treatment at the time of initial episode, and late
recurrence associated with underlying autoimmune (con-
nective tissue) diseases. Though it was statistically insignif-
icant, due to the small number of cases, connective
tissue diseases were considered to be associated with recur-
rence; the positive rate of FANA was significantly higher
in the recurrent cases compared to the non-recurrent
cases. Previously, Kucukardali et al. reported that FANA
positivity (23.4% vs. 3%) and SLE association rates (28% vs.
9%) were significantly higher in East Asia and the Far East
compared to those in Europe.8 However, there was a chance
that recurrent disease with positive FANA might simply
reflect the overlap between SLE and Kikuchi’s disease.
Cervical lymphadenitis could be the initial presentation of
SLE in some patients, which is supported by the finding that
three among 21 patients with ‘recurrent’ disease developed
SLE in the follow-up period, in contrast to none among
81 patients with ‘non-recurrent’ disease. A prospective
cohort study is required to clarify this point. On the other
hand, self-limiting thyroiditis was only found in the non-
recurrent cases. We tried to analyze the differences
between early relapse and late recurrence, but no contri-
buting factor was identified, which would be the limitation
of a retrospective study.
In conclusion, Kikuchi’s disease took a self-limiting clinical
course in most cases, but the recurrence rate was higher
compared to that of previous reports. Kikuchi’s disease might
be a phenotype of diverse disease entities. The prognosis is
different according to the causative illness. The FANA test
would be useful in predicting the patient’s prognosis.
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